| Similar Articles |
|---|
 |
The Motley Fool
November 10, 2006
Brian Gorman |
Albany Molecular Plays the Odds Third-quarter results show that the chemistry services outfit continued to slog through some tough times. Heightened activity in its riskier side business suggests that 2007 might not bring a fatter bottom line.   |
The Motley Fool
February 13, 2006
Brian Gorman |
Albany Molecular's Royalty Squeeze Declining royalty revenue is likely to keep buffeting the contract services provider. Investors, take note. |
The Motley Fool
May 11, 2006
Brian Gorman |
Albany Molecular Stabilizes The chemistry services company's results are still slumping, but the worst appears to be over. Investors, take note. |
The Motley Fool
August 2, 2006
Brian Gorman |
Albany Molecular Bouncing Back The small drug development services firm continues to progress with its turnaround. Investors, take note. |
The Motley Fool
November 20, 2008
Brian Orelli |
Sanofi Breathing Easier Drugmaker Sanofi-Aventis settles a few patent disputes with generic-drugmaker nemeses. |
The Motley Fool
May 5, 2004
Brian Gorman |
Albany Molecular Gets Out-Outsourced Albany Molecular Research, provider of chemistry services to biotech and pharmaceutical clients, is suffering from the loss of business to low-cost competitors overseas. |
Chemistry World
January 28, 2015
Rebecca Trager |
Roche chases bolt-on acquisitions as it pushes into genomics A recent spending spree by Roche is intended to take advantage of emerging molecular information and genomic analysis, as the company anticipates that the field will play an increasingly important role for future medicines and diagnostics. |
The Motley Fool
February 7, 2006
Stephen D. Simpson |
Barr None Bargain hunters are probably going to come up short when it comes to assessing Barr Pharmaceuticals' stock, but a fairly rich package of opportunities should keep growth strong for the immediate future. |
The Motley Fool
May 5, 2006
Stephen D. Simpson |
Sanofi-Aventis Waits It Out This is the hurry up-and-wait part of the French pharma's story, with product approvals on the way soon, investors hope. |
The Motley Fool
December 16, 2011
Brian Orelli |
Biotech Royalties, Almost as Good as Cash They're flexible, and all royalties have value. |
The Motley Fool
January 30, 2007
Ralph Casale |
Molecular Devices Acquired Successful integration of companies like Molecular Devices and improvement of operating margins in the pharmaceutical contract research business unit should reward shareholders well. |
The Motley Fool
April 29, 2004
Bill Mann |
Schizophrenia Saves Bristol-Myers Big gains in currencies and schizophrenia drugs help offset some key losses. |
BusinessWeek
February 26, 2007
Arlene Weintraub |
The Power Of The Pipeline Bristol-Myers Squibb is beset with troubles, but its new-drug potential makes it a target. |
The Motley Fool
February 28, 2008
Brian Lawler |
Third Wave Making Tiny Ripples Small molecular-diagnostics developer Third Wave Technologies could be poised for big returns. |
Chemistry World
November 2007 |
Book Reviews A review of books on: good clinical & laboratory practices, green chemistry, environmental chemistry, organic reactions in water, universal asymmetry, and molecular models for fluids. |
Chemistry World
October 16, 2007
Ned Stafford |
Germany's 900m Euro Molecular Imaging Drive Five German companies and the Federal Ministry of Education and Research are to spend almost a billion euros in an effort to strengthen the nation's international competitiveness in molecular imaging, which will require a large dose of nanotechnology research. |
Chemistry World
October 2008
Derek Lowe |
Column: In the pipeline The author seeks a cure for 'compound bloat' |
Chemistry World
August 13, 2013
Uwe Pischel |
Molecular logic-based computation This book, by A. Prasanna de Silva, will serve the expert, as well as interested scientists from other specialties related to any aspect of molecular logic. |
The Motley Fool
November 8, 2005
Stephen D. Simpson |
Teva Is No Generic Generics Firm Although 2005 wasn't a great year for generics on the whole, 2006 is shaping up to be pretty interesting for Teva. Is it time to buy these shares? |
